1-<4-(2-Diaethylamino-aethoxy)-phenyl>-1-<4-chlor-phenyl>-2-phenyl>-aethanol | 115208-53-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1-<4-(2-Diaethylamino-aethoxy)-phenyl>-1-<4-chlor-phenyl>-2-phenyl>-aethanol
• 英文别名: 1-<4-Chlor-phenyl>-1-<4-(2-diaethylamino-aethoxy)-phenyl>-2-phenyl-aethanol；1-(4-Chlorophenyl)-1-[4-[2-(diethylamino)ethoxy]phenyl]-2-phenylethanol
• CAS: 115208-53-2
• 化学式: C₂₆H₃₀ClNO₂
• 分子量: 423.983
• InChiKey: NWZZKKWBEXLTLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  30
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
  申请人：NeoRx Corporation

  公开号：US20020068731A1

  公开（公告）日：2002-06-06

  A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): 1 wherein Z is C═O or a covalent bond; Y is H or O(C 1 -C 4 )alkyl, R 1 and R 2 are individually (C 1 -C 4 )allyl or together with N are a saturated heterocyclic group, R 3 is ethyl or chloroethyl, R 4 is H, R 5 is I, O(C 1 -C 4 )alkyl or H and R 6 is I, O(C 1 -C 4 )alkyl or H with the proviso that when R 4 , R 5 , and R 6 are H, R 3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to elevate the level of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene, toremifene or salts thereof. Further provided is a method for identifying an agent that elevates the level of TGF-beta. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifen or structural analogs thereof, including compounds of formula (I).

  一种通过施用式（I）化合物治疗或预防心血管疾病的方法： 1 其中 Z 是 C&boxH；O 或共价键；Y 是 H 或 O(C 1 -C 4 烷基，R 1 和 R 2 分别是（C 1 -C 4 )烯丙基或与 N 一起为饱和杂环基团，R 3 是乙基或氯乙基，R 4 是 H，R 5 是 I、O（C 1 -C 4 烷基或 H，而 R 6 是 I、O(C 1 -C 4 烷基或 H，但当 R 4 , R 5 和 R 6 为 H，R 3 不是乙基；或其药学上可接受的盐，可有效提高 TGF-beta 的水平，从而治疗和/或预防动脉粥样硬化、血栓形成、心肌梗塞和中风等疾病。有用的化合物包括依多昔芬、托瑞米芬或其盐类。本发明还提供了一种鉴定可提高 TGF-beta 水平的制剂的方法。本发明的另一个实施方案是一种测定体外 TGF-beta 的检测方法或试剂盒。本发明还提供了一种治疗方法，包括通过施用他莫昔芬或其结构类似物（包括式(I)化合物）来抑制与程序性血管创伤相关的平滑肌细胞增殖。
• Method to determine TGF-beta
  申请人：NeoRx Corporation

  公开号：US20020182659A1

  公开（公告）日：2002-12-05

  A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (1): 1 wherein Z is C═O or a covalent bond; Y is H or O(C 1 -C 4 )alkyl, R 1 and R 2 are individually (C 1 -C 4 )alkyl or together with N are a saturated heterocyclic group, R 3 is ethyl or chloroethyl, R 4 is H or together with R 3 is —CH 2 CH 2 — or —S—, R 5 is I, O(C 1 -C 4 )alkyl or H, and R 6 is I, O(C 1 -C 4 )alkyl or H with the proviso that when R 4 , R 5 , and R 6 are H, R 3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to activate or stimulate production of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene and salts thereof. Further provided is a method for identifying a compound that is a TGF-beta activator or production stimulator is provided. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifen or structural analogs thereof, including compounds of formula (I).

  一种通过施用式（1）化合物治疗或预防心血管疾病的方法： 1 其中 Z 是 C&boxH；O 或共价键；Y 是 H 或 O(C 1 -C 4 )烷基，R 1 和 R 2 分别是（C 1 -C 4 )烷基或与 N 一起为饱和杂环基团，R 3 是乙基或氯乙基，R 4 是 H 或与 R 3 是-CH 2 CH 2 - 或-S-，R 5 是 I、O(C 1 -C 4 烷基或 H，而 R 6 是 I、O（C 1 -C 4 烷基或 H，但当 R 4 , R 5 和 R 6 为 H，R 3 不是乙基；或其药学上可接受的盐，可有效激活或刺激 TGF-beta 的产生，从而治疗和/或预防动脉粥样硬化、血栓形成、心肌梗塞和中风等疾病。有用的化合物包括艾多昔芬及其盐类。本发明还提供了一种用于鉴定 TGF-beta 激活剂或生成刺激剂的化合物的方法。本发明的另一个实施方案是一种测定体外 TGF-beta 的检测方法或试剂盒。本发明还提供了一种治疗方法，包括通过施用他莫昔芬或其结构类似物（包括式 (I) 化合物）来抑制与程序性血管创伤相关的平滑肌细胞增殖。
• Compounds and therapies for the prevention of vascular and non-vascular pathologies
  申请人：NeoRx Corporation

  公开号：US20030064970A1

  公开（公告）日：2003-04-03

  The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.

  本发明提供了一种治疗哺乳动物的方法，该哺乳动物具有或有可能具有与 TGF-beta 缺乏有关的适应症，该方法包括施用一种或多种能有效提高 TGF-beta 水平的制剂。本发明还提供了能提高TGF-beta水平的新型化合物、包含能提高TGF-beta水平的化合物的药物组合物，以及检测与内皮细胞活化相关的疾病的方法。
• Prevention and treatment of cardiovascular pathologies
  申请人：Grainger J. David

  公开号：US20060029986A1

  公开（公告）日：2006-02-09

  A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): wherein Z is C═O or a covalent bond; Y is H or O(C 1 -C 4 )alkyl, R 1 and R 2 are individually (C 1 -C 4 )alkyl or together with N are a saturated heterocyclic group, R 3 is ethyl or chloroethyl, R 4 is H or together with R 3 is —CH 2 —CH 2 — or —S—, R 5 is I, O(C 1 -C 4 )alkyl or H and R 6 is 1, O(C 1 -C 4 )alkyl or H with the proviso that when R 4 , R 5 , and R 6 are H, R 3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to activate or stimulate production of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene and salts thereof. Further provided is a method for identifying a compound that is a TGF-beta activator or production stimulator is provided. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifen or structural analogs thereof, including compounds of formula (I).

  一种通过施用式(I)化合物治疗或预防心血管疾病的方法： 其中 Z 是 C═O 或共价键；Y 是 H 或 O（C 1 -C 4 )烷基，R 1 和 R 2 分别是（C 1 -C 4 )烷基或与 N 一起为饱和杂环基团，R 3 是乙基或氯乙基，R 4 是 H 或与 R 3 是-CH 2 -CH 2 - 或-S-，R 5 是 I、O(C 1 -C 4 烷基或 H，而 R 6 是 1、O(C 1 -C 4 烷基或 H，但当 R 4 , R 5 和 R 6 为 H，R 3 不是乙基；或其药学上可接受的盐，可有效激活或刺激 TGF-beta 的产生，从而治疗和/或预防动脉粥样硬化、血栓形成、心肌梗塞和中风等疾病。有用的化合物包括艾多昔芬及其盐类。本发明还提供了一种用于鉴定 TGF-beta 激活剂或生成刺激剂的化合物的方法。本发明的另一个实施方案是一种测定体外 TGF-beta 的检测方法或试剂盒。本发明还提供了一种治疗方法，包括通过施用他莫昔芬或其结构类似物（包括式 (I) 化合物）来抑制与程序性血管创伤相关的平滑肌细胞增殖。
• PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES
  申请人：NEORX CORPORATION

  公开号：EP0833624A2

  公开（公告）日：1998-04-08